Deal focus: Antengene targets unmet cancer problems
Chinese drug developer Antengene wins backing from the likes of Boyu Capital and FountainVest Partners for a pipeline of treatments that address the country's growing cancer problem
Despite being the world’s second-largest pharmaceutical market, China isn’t known for its prowess in drug innovation. The country has some of the highest incidence rates for cancer, diabetes and liver...
More on Greater China
Latest News
Philippines PE: Power dynamics
A virtually impenetrable middle market under the control of incumbent conglomerates is the least governable of the systemic obstacles facing private equity hopefuls in the Philippines
GGV backs Singapore dental 3D printing company
GGV Capital has joined a group of investors in a venture round of undisclosed size for Structo, a Singapore-based 3D printing company focused on the dental industry.
Ant Financial invests $92m in Chinese e-signature provider
TSign – a China-based electronic signature service provider – has received RMB650 million ($92 million) in Series C funding led by Alibaba Group affiliate Ant Financial. Other investors include Gobi Partners and Eminence Ventures.